3D-printed lymph nodes could speed CAR T access

A team in Spain has 3D-printed lymph-node-like structures that help human T-cells become CAR T-cells more efficiently and faster, potentially lowering expensive chemical use and shortening a process that can take about a month—two bottlenecks that currently ke

When CAR T-cell therapy is ready, it can change the course of certain cancers fast. But getting there is a race against time—and a problem of cost. The therapy relies on a patient’s own T-cells being extracted. genetically engineered to target cancer. then multiplied and returned to the body. That turnaround can take about a month. and even a single round can cost more than £280. 000—prices and delays that effectively confine access to wealthier countries.

In that window, some patients may deteriorate so much that they can’t receive the treatment. “When you’re treating very sick patients. some patients might never get the therapy because they’ve deteriorated so much in the three or so weeks it might take to make the CAR T therapy. ” says David Coe at CoED Biosciences in Cardiff. UK. who was not involved in the research.

CAR T-cell therapy starts with T-cells taken from someone’s blood, then reprogrammed to recognize and destroy cancer cells. Typically. the process involves mixing T-cells with tiny beads that activate their proliferation. along with a harmless virus that delivers the genetic code for a chimeric antigen receptor (CAR) designed to target molecules on the surface of cancer cells. In standard protocols, about 30 to 70 per cent of T-cells are successfully reprogrammed, with higher rates generally linked to better outcomes.

After that, the cells are multiplied for a few weeks before being infused back into the body, which means the entire process can take about a month. Even the biology comes with a logistical cost: just one round can top £280,000.

To chip away at those barriers. Judit Guasch Camell at the Materials Science Institute of Barcelona. Spain. and her colleagues 3D printed a gel designed to form structures resembling the texture and arrangement of human lymph nodes—the places where T-cells are normally activated when they detect a threat. The idea rests on earlier findings that T-cells respond not only to chemical signals. but also to the physical properties of lymph nodes. which can help them activate and proliferate more efficiently.

In the standard CAR T approach, the cells are activated while they interact with flat plastic surfaces—lab dishes or bags that don’t provide the same tactile cues. Guasch Camell said these missing physical signals limit both proliferation and the uptake of the CAR genetic code.

To test the 3D design, the researchers added human T-cells, a virus encoding a cancer-specific CAR, and the beads to the lymph-node-like structures. For comparison, they mixed the same components in plastic dishes. Then they checked what happened.

Five days later. the results were striking: about 50 per cent of the T-cells grown with the standard approach had successfully become CAR T-cells. compared with 75 per cent in the lymph-node method. Coe said the higher conversion rate suggests the approach could reduce the amount of extremely expensive chemicals needed to genetically engineer CAR T-cells.

The cells didn’t just convert more effectively—they also grew faster. The T-cells expanded about twice as fast in the lymph node structures as in the standard approach. Coe said that speed could reduce labour costs and, just as importantly, help ensure patients are treated before it’s too late.

The sequence is clear across the findings: changing the physical environment improved both the share of cells that became CAR T-cells and the pace at which they multiplied. That combination directly targets two of the therapy’s most stubborn bottlenecks—time and cost.

Still, the work is only a step toward wider access. “It’s about making immunotherapies [treatments that use our immune system to fight cancer] accessible worldwide. including in lower- and middle-income countries. ” says Gillian Griffiths at the University of Cambridge. who was not involved in the research.

Further studies. Coe says. are needed to determine how easily the method can be scaled up and what precise cost it would bring once production moves beyond the lab setting. For now. though. the prospect is hard to ignore: 3D-printed lymph-node-like structures may offer a faster. more efficient way to prepare CAR T-cells—potentially widening access for patients who don’t have the luxury of waiting.

CAR T-cell therapy 3D printing lymph nodes immunotherapy T-cells genetic engineering biophysical immunoengineering cancer treatment accessibility scaling up